A Study of LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring
Latest Information Update: 20 Apr 2023
Price :
$35 *
At a glance
- Drugs Insulin glargine (Primary) ; Insulin lispro (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms PRONTO-Time in Range
- Sponsors Eli Lilly and Company
- 07 Apr 2023 Primary endpoint has been met. (Change From Baseline in Percentage of Time With Continuous Glucose Monitoring (CGM) Sensor Glucose Values Between 70-180 Milligrams/Deciliter (mg/dL) (3.9-10.0 Millimoles/Liter [mmol/L]) (Both Inclusive) During Daytime Period at Week 12)
- 07 Apr 2023 Results published in the Diabetes Therapy
- 24 Feb 2022 Status changed from active, no longer recruiting to completed.